

## Medical Policy

Carvykti™ (ciltacabtagene autoleuce)	
<b>MEDICAL POLICY NUMBER</b>	MED_Clin_Ops-122
<b>CURRENT VERSION EFFECTIVE DATE</b>	01/01/2024
<b>APPLICABLE PRODUCT AND MARKET</b>	Individual Family Plan: ALL Small Group: ALL Medicare Advantage: ALL

Brand New Day/Central Health Medicare Plan develops policies and makes coverage determinations using credible scientific evidence including but not limited to MCG™ Health Guidelines, the ASAM Criteria™, and other third party sources, such as peer-reviewed medical literature generally recognized by the relevant medical community, physician specialty society recommendations, and expert opinion as relevant to supplement those sources. Brand New Day/Central Health Medicare Plan Medical Policies, MCG™ Guidelines, and the ASAM Criteria™ are not intended to be used without the independent clinical judgment of a qualified health care provider considering the individual circumstances of each member's case. The treating health care providers are solely responsible for diagnosis, treatment, and medical advice. Members may contact Brand New Day/Central Health Medicare Plan Customer Service at the phone number listed on their member identification card to discuss their benefits more specifically. Providers with questions about this Brand New Day/Central Health Medicare Plan policy may contact the Health Plan. Brand New Day/Central Health Medicare Plan policies and practices are compliant with federal and state requirements, including mental health parity laws.

If there is a difference between this policy and the member specific plan document, the member benefit plan document will govern. For Medicare Advantage members, Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), govern. Refer to the CMS website at <http://www.cms.gov> for additional information.

Brand New Day/Central Health Medicare Plan medical policies address technology assessment of new and emerging treatments, devices, drugs, etc. They are developed to assist in administering plan benefits and do not constitute an offer of coverage nor medical advice. Brand New Day/Central Health Medicare Plan medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Brand New Day/Central Health Medicare Plan does not provide health care services and, therefore, cannot guarantee any results or outcomes. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies are updated based on changes in the evidence and healthcare coding and therefore are subject to change without notice. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). MCG™ and Care Guidelines® are trademarks of MCG Health, LLC (MCG).

## PURPOSE

The purpose of this policy is to establish the clinical review criteria that support the determination of medical necessity for Carvykti™ (ciltacabtagene autoleucl) therapy.

## POLICY

### Prior Authorization and Medical Review is required.

Coverage for Carvykti will be provided for one treatment course (1 dose of Carvykti) and may not be renewed.

- Max Units (per dose and over time): 1 billable unit (1 dose of up to 100 million autologous CAR-positive viable T-cells)

### Initial

- A. Patient is at least 18 years of age; **AND**

### Medical Policy

- B. Healthcare facility has enrolled in the CARVYKTI REMS Program and training has been given to providers on the management of cytokine release syndrome (CRS) and neurological toxicities; **AND**
- C. Patient has not received prior CAR-T or B-cell maturation antigen (BCMA) targeted therapy; **AND**
- D. Patient has not received prior allogeneic hematopoietic stem cell transplant within 6 months prior to therapy; **AND**
- E. Patient does not have an active infection or inflammatory disorder; **AND**
- F. Patient has not received live vaccines within 6 weeks prior to the start of lymphodepleting chemotherapy, and will not receive live vaccines during ciltacabtagene autoleucl treatment, and until immune recovery following treatment; **AND**
- G. Patient has been screened for cytomegalovirus (CMV), hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines prior to collection of cells (leukapheresis); **AND**
- H. Prophylaxis for infection will be followed according to standard institutional guidelines; **AND**
- I. Used as single agent therapy (not applicable to lymphodepleting or additional chemotherapy while awaiting manufacture); **AND**
- J. Patient does not have known central nervous system (CNS) involvement with myeloma or a history or presence of clinically relevant, active, CNS pathology; **AND**
- K. Patient does not have active or a history of plasma cell leukemia; **AND**
- L. Patient has an ECOG performance status of 0-1; **AND**

### Multiple Myeloma

- A. Patient has relapsed or refractory disease; **AND**
- B. Patient has received at least four (4) prior therapies, including a proteasome inhibitor (e.g., bortezomib, etc.), an immunomodulatory agent (e.g., lenalidomide, thalidomide, etc.) and an anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab, etc.).

### Renewal

- A. Coverage cannot be renewed.

### LIMITATIONS/EXCLUSIONS

- 1) Any indication other than those listed above due to insufficient evidence of therapeutic value

### DEFINITIONS

- A. CARVYKTI™ (ciltacabtagene autoleucl) suspension for intravenous infusion. Initial U.S. Approval: 2022

### CODING

Applicable NDC Codes	
57894-0111-xx	Carvykti suspension for intravenous infusion [A single dose of Carvykti contains a cell suspension of up to 1 x 10 <sup>8</sup> CAR-positive T cells in one or more infusion bags]; 30 mL and 70 mL infusion bags and metal cassettes

## Medical Policy

### Applicable Procedure Code

Q2056	Ciltacabtagene autoleucl, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
-------	--

### Applicable ICD-10 Codes

C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma, in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.32	Solitary plasmacytoma in relapse
D47.2	Monoclonal gammopathy
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

## EVIDENCE BASED REFERENCES

1. Carvykti [package insert]. Horsham, PA; Janssen Biotech, Inc., March 2022. Accessed July 2022.

## Policy History

This policy has been approved by the approval body listed below or has received other necessary approval pursuant to Brand New Day/Central Health Medicare Plan Care's policies on clinical criteria and policy development.

<b>Approval Body</b>	Pharmacy and Therapeutics Committee
<b>Original Effective Date</b>	July 26, 2022
<b>Revision Date</b>	February 28, 2023 - Updated HCPCS for Carykti (Q2056) March 01, 2023 – Adopted by MA UMC January 01, 2024 - Updated to Brand New Day/Central Health Medicare Plan/Central Health Medicare Plan